Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Collaborators:
Janssen Pharmaceuticals
University of Cincinnati
Information provided by (Responsible Party):
Lindner Center of HOPE
ClinicalTrials.gov Identifier:
NCT00277654
First received: January 12, 2006
Last updated: December 12, 2011
Last verified: December 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Publications: